TriSalus Life Sciences, Inc. TLSI
3.48 USD -0.15 (-4.13%)
At closeNov 3, 2026, 4:39 PM EST
3.43 -0.05 -1.44%
After hours · Nov 3, 4:39 PM ET
3.40 Day range 3.77
2.52 52-week range 7.50
- YTD
- -50.14%
- 1 year
- -26.11%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Dyadic International (NASDAQ:DYAI) stock rose 13.4% to $0.43 during Tuesday's pre-market session. The market value of their outstanding shares is at $15.0 million. Aethlon Medical…
businesswire.com TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care…
businesswire.com TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an…
benzinga.com Full Transcript: TriSalus Life Sciences Q2 2026 Earnings Call TriSalus Life Sciences (NASDAQ:TLSI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs…
defenseworld.net Reviewing Innovative Eyewear (NASDAQ:LUCY) and TriSalus Life Sciences (NASDAQ:TLSI) TriSalus Life Sciences (NASDAQ: TLSI - Get Free Report) and Innovative Eyewear (NASDAQ: LUCY - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will…
benzinga.com Crude Oil Gains 1%; Cintas Earnings Top Views U.S. stocks fell Wednesday, led by a 1.1% Nasdaq drop. Cintas beat estimates and raised guidance; oil gained while gold, silver and copper declined.
benzinga.com TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support The U.S. Food and Drug Administration (FDA) on Wednesday granted 510(k) clearance for TriSalus Life Sciences Inc.'s (NASDAQ:TLSI) TriNav Advance, the newest addition to its Pressure-Enabled Drug…
benzinga.com TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support TriSalus Life Sciences secured FDA clearance for its TriNav Advance device, but shares face critical resistance levels amid a recent slide.
benzinga.com TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday U.S. stocks were lower, with the Nasdaq Composite falling over 100 points on Wednesday.
benzinga.com TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
benzinga.com Microsoft To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for Meta, Microsoft, Valero and others; Microsoft upgraded to Buy, while KB Home and RTX targets fell.
benzinga.com Market-Moving News for September 23rd IONQ: 14% | IonQ shares are trading higher after the company announced that researchers demonstrated the development and testing of the first end-to-end real-time quantum error correction decoder…
benzinga.com HC Wainwright & Co. Maintains Buy on TriSalus Life Sciences, Raises Price Target to $12 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and raises the price target from $11 to $12.
benzinga.com Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's after-market session. The company's market cap stands at $1.1 million. Bullfrog AI Hldgs (NASDAQ:BFRG)…
businesswire.com TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and its…
benzinga.com This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiate coverage: Buy ratings for Robinhood ($170), TriSalus ($11), Kodiak AI ($8); Underperform for Deckers ($70).
benzinga.com HC Wainwright & Co. Initiates Coverage On TriSalus Life Sciences with Buy Rating, Announces Price Target of $11 HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and announces Price Target of $11.
businesswire.com TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference.
marketbeat.com TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference TriSalus Life Sciences NASDAQ: TLSI outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity's Global Growth Conference, with management emphasizing…
marketbeat.com TriSalus Life Sciences Q2 Earnings Call Highlights TriSalus Life Sciences NASDAQ: TLSI reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system…
seekingalpha.com TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript
benzinga.com TriSalus Life Sciences Affirms FY2026 Sales Guidance of $54.000M-$57.000M vs $52.396M Est TriSalus Life Sciences (NASDAQ:TLSI) affirms FY2026 sales outlook from $54.000 million-$57.000 million to $54.000 million-$57.000 million vs $52.396 million estimate.- benzinga.com TriSalus Life Sciences Q2 EPS $(0.16) Misses $(0.15) Estimate, Sales $11.407M Beat $10.267M Estimate TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 40.74 percent increase over…
businesswire.com TriSalus Life Sciences Reports Second Quarter 2026 Results DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its…
businesswire.com TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care…
businesswire.com TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (NASDAQ: TLSI). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI). Such investors…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (NASDAQ: TLSI). Such investors are…
globenewswire.com TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES, June 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TriSalus Life…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI). Such investors…
prnewswire.com TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TriSalus Life…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (NASDAQ: TLSI). Such investors are…
benzinga.com Lake Street Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $8 Lake Street analyst Frank Takkinen maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and lowers the price target from $10 to $8.
benzinga.com Nasdaq Surges Over 1%; Alibaba Shares Gain After Q4 Results US stocks mixed, Nasdaq up 200 points. Dow down 0.43%, Nasdaq up 0.79%, S&P 500 up 0.27%. Communication services up 1.6%, utilities down 1.4%. Alibaba shares up 6% after reporting mixed Q4 results.…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Dow Falls 200 Points; US Producer Prices Surge In April US stocks mixed as Dow drops over 200 points on opening. Nasdaq up 0.13%, S&P 500 down 0.13%. Tech sector up 0.4%, utilities down 1.7%. PPI rose 1.4% in April.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com TriSalus Life Sciences Q1 2026 Earnings Call: Complete Transcript - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com TriSalus Life Sciences Lowers FY2026 Sales Guidance from $60.000M-$62.000M to $54.000M-$57.000M vs $59.960M Est TriSalus Life Sciences (NASDAQ:TLSI) lowers FY2026 sales outlook from $60.000 million-$62.000 million to $54.000 million-$57.000 million vs $59.960 million estimate.
benzinga.com TriSalus Life Sciences Q1 EPS $0.03 Beats $(0.16) Estimate, Sales $8.899M Miss $10.440M Estimate TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.16) by 118.75 percent. This is a 107.69 percent increase over…- benzinga.com TriSalus Life Sciences Announces Publication Of Study On Pressure-Enabled Drug Delivery Used In Trans Arterial Chemoembolization And Radioembolization The study, titled "Clinical Outcomes of Pressure-Enabled Drug Delivery (PEDD) for Trans-Arterial Chemoembolization (TACE) and Radioembolization (TARE)," was published online on April 9, 2026 in the…
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com TriSalus Life Sciences Announced The Initiation Of Patient Enrollment For The PREDICTT Clinical Trial, A Prospective Study Designed To Evaluate Its Novel Pressure-enabled Drug Delivery Approach In Patients With Primary Or Metastatic Liver Tumors TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to…
- benzinga.com Earnings Scheduled For March 5, 2026
- benzinga.com Earnings Scheduled For November 13, 2025
- benzinga.com Earnings Scheduled For August 12, 2025
- benzinga.com Earnings Scheduled For May 15, 2025